Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 21Brain Neoplasms 7Neoplasms 5Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Lung Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Hematologic Neoplasms 3Thyroid Neoplasms 2Lymphoma 2Leukemia, Hairy Cell 2Glioma 2Endometrial Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Skin Neoplasms 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Peripheral Nervous System Neoplasms 1

Interventions

Fulvestrant 3Alpelisib 3parsaclisib 2Paclitaxel 2Irinotecan 2Cetuximab 2Carboplatin 2tanezumab 1talazoparib 1sotorasib 1serabelisib 1sapanisertib 1ruxolitinib 1olaparib 1niraparib 1liposomal doxorubicin 1inavolisib 1dapagliflozin 1ceralasertib 1binimetinib 1berzosertib 1avelumab 1Vemurafenib 1Topotecan 1Taxes 1SF 1126 1Oxaliplatin 1Lomustine 1Leuprolide 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hereditary Sensory and Autonomic Neuropathies × binimetinib × Clear all
NCT01320085 2024-01-24

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Pfizer

Phase 2 Completed
183 enrolled 35 charts
Dermatologic

Melanoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡